key: cord-0866978-2u5zxc2i authors: Yu, B.; Wang, D. W.; Li, C. title: Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19 date: 2020-05-01 journal: nan DOI: 10.1101/2020.04.27.20073379 sha: b32f36f5c880d8ddb7b526b91088a4dd2b4b1252 doc_id: 866978 cord_uid: 2u5zxc2i Importance: Coronavirus disease 2019 (COVID-19) is a pandemic with no specific drugs and high mortality. The most urgent thing is to find effective treatments. Objective: To determine whether hydroxychloroquine application may be associated with a decreased risk of death in critically ill COVID-19 patients and what is potential mechanism. Design, Setting and Patients: This retrospective study included all 568 critically ill COVID-19 patients who were confirmed by pathogen laboratory tests despite antiviral treatment and had severe acute respiratory distress syndrome, PAO2/FIO2 <300 with need of mechanical ventilation in Tongji Hospital, Wuhan, between February 1 of 2020 to April 8 of 2020. All 568 patients received comparable basic treatments including antiviral drugs and antibiotics, and 48 of them additionally received oral hydroxychloroquine (HCQ) treatment (200 mg twice a day for 7-10 days). Primary endpoint is mortality of patients, and inflammatory cytokines levels were compared between hydroxychloroquine and non-hydroxychloroquine (NHCQ) treatments. MAIN OUTCOMES AND MEASURES: In-hospital death and hospital stay time (day) were obtained, level of inflammatory cytokine (IL-6) was measured and compared between HCQ and NHCQ treatments. RESULTS: The median age of 568 critically ill patients is 68 (57, 76) years old with 37.0% being female. Mortalities are 18.8% (9/48) in HCQ group and 45.8% (238/520) in NHCQ group (p<0.001). The time of hospital stay before patient death is 15 (10-21) days and 8 (4 - 14) days for the HCQ and NHCQ groups, respectively (p<0.05). The level of inflammatory cytokine IL-6 was significantly lowered from 22.2 (8.3-118.9) pg/mL at the beginning of the treatment to 5.2 (3.0-23.4) pg/ml (p<0.05) at the end of the treatment in the HCQ group but there is no change in the NHCQ group. CONCLUSIONS AND RELEVANCE: Hydroxychloroquine treatment is significantly associated with a decreased mortality in critically ill patients with COVID-19 through attenuation of inflammatory cytokine storm. Therefore, hydroxychloroquine should be prescribed for treatment of critically ill COVID-19 patients to save lives. Since the breakout of infection by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at the end of 2019 in Wuhan, China 1 More recently, plasma of convalescent patients was used in Wuhan to manage refractory patients successfully but the scope of this treatment is greatly constrained due to the limited supply of effective plasma. Chloroquine and hydroxychloroquine are two classic drugs 5 , which were originally used to treat malaria. In recent years, repurpose of existing drugs such as chloroquine class of drugs for other diseases has received increasingly growing attention 5, 6 . Chloroquine and hydroxychloroquine have been used to treat rheumatological and immunological diseases because their All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The key to reduce mortality of COVID-19, however, is to cure critically ill patients. This study demonstrates that hydroxychloroquine application, a less toxic derivative of chloroquine, is significantly associated with a decreased mortality in critically ill patients with COVID-19 by attenuating the inflammatory cytokine storm. This investigation is a retrospective study involving critically ill patients with All patients have medical history and imaging characteristics of COVID-19 and have been confirmed with SARS-CoV-2 infection by laboratory tests. In All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted May 1, 2020. . https://doi.org/10.1101/2020.04.27.20073379 doi: medRxiv preprint addition, all patients were confirmed by chest computed tomography (CT) and SARS-CoV-2 pathogenic test. The inclusion for critically ill patients has to meet one of the following criteria: 1) patients had respiratory failure and needed mechanical ventilation; 2) patients had septic shock during hospitalization; 3) patients with other organ failures that required monitoring and treatment by intensive care unit. In this study, we included all critically ill patients with hospitalization during the epidemic period from February 1 of 2020 to April 8 of 2020. Health care data of COVID-19 patients, including medical history, chest CT, and laboratory tests, in-hospital therapies, and clinical deposits (death or cured discharge), were extracted by data coordinators through the electronic medical records. Laboratory test results included inflammatory cytokines and counts of white blood cells in peripheral blood. Continuous values were expressed as medians and interquartile range (Q1-Q3) and categorical variables as counts and percentages. The comparisons of continuous values between groups were performed with Wilcoxon rank-sum tests. For paired continuous variables, paired sample Wilcoxon rank test was used. Categorical variables were compared using Chi-square test. Survival curves was described by Kaplan-Meier method and compared with the log-rank test. Cox regression were performed to determine hazard ratios (HRs) and 95% confidence intervals (CIs). In the mulitivariable model, we adjusted for age, sex, history of hypertension, diabetes mellitus, coronary heart disease, and COPD, and oxygen saturation, as well as baseline treatment drugs. All comparisons were two-tailed, and p < 0.05 was considered as statistically significant. All statistical analyses were performed with R packages (version 3.1.4, Vienna, Austria). All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted May 1, 2020. . https://doi.org/10.1101/2020.04.27.20073379 doi: medRxiv preprint From February 1 of 2020, through April 8 of 2020, a total 568 critically ill COVID-19 patients were admitted to Tongji Hospital, 358 males and 210 females. Median ages were 68 years old; 48 patients received hydroxychloroquine treatments (HCQ) (oral 200 mg twice per day for 7-10 days) and remaining 520 receiving basic treatments (non-hydroxychloroquine treatments, NHQC). Between these two groups, baseline characteristics including age, genders, original comorbidities, as well as severity of disease were not different (table 1) . In total of 568 patients, 247 patients died (mortality was 43.5%). In order to eliminate the influence of confounding factors, we performed Cox All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Laboratory tests showed that in HCQ group, IL-6 level in plasma was 5.2 (Figure 2 ). Furthermore, we analyzed the change of IL-6 level during the hospitalization period and found that IL-6 level was lowered after HCQ application and kept the lower level stable during therapy period. However, interestingly, after hydroxychloroquine treatment stopped, inflammatory mediator IL-6 level went up to control level ( Figure 3 ). All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This retrospective study found that hydroxychloroquine application is significantly associated with a decreased mortality in critically ill patients with COVID-19 and lower level of IL-6, one of most inflammatory cytokines. We also found that the length of hospital stay in the hydroxychloroquine-treated non-survivors is longer than in non-hydroxychloroquine-treated non-survivors, suggesting that hydroxychloroquine could prolong the lifetime of critically ill patients even if their lives were eventually lost, which further supports that hydroxychloroquine has therapeutic effects for critically ill patients of COVID-19. Importantly, we found that the role that hydroxychloroquine application associated with a decreased plasma IL-6 level is highly consistent with the duration of its administration, and once the drug stops, plasma IL-6 level rises up to control level. We have noted that hydroxychloroquine has in vitro antiviral effects on several viruses, including SARS, and SARS-CoV-2 7-10 , which may contribute directly to its therapeutic effect to COVID-19 patients. However, the anti-SARS-CoV2 action of chloroquine does not seems to account for the significant efficiency to critically ill patients in our cohort. COVID-19 patients displayed obvious immunity disorders, showing marked reduction in lymphocyte numbers in peripheral blood and lymphatic tissues, but huge amount of lymphocyte infiltration in lungs as well as in other critical organs such as heart. Many patients showed symptoms of cytokine storm with markedly-elevated levels of the proinflammatory cytokine IL-6, suggesting overactivated immune responses 11 . Anti-IL-6 antibody, Tocilizumab, has been been shown to be an effective treatment option for COVID-19 patients with a risk of cytokine storms. 12 In this study, we demonstrate that hydroxychloroquine can mimic the effect of anti-IL-6 antibody by observing decreased levels of Il-6 in the critically ill COVID-19 patients after All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 13, 14 , and inhibit proinflammatory cytokines through inhibition of lysosomal-autophagy pathways 14 Additionally, a decreased plasma IL-6 level after hydroxychloroquine use is highly consistent with its application period and after stopped its role disappear and IL-6 level increases to the level of non-hydroxychloroquine patients. This finding indicates that we need to adjust our treatment regimen, that is, to keep use hydroxychloroquine until patients are completely cured. In summary, this retrospective study demonstrates that hydroxychloroquine application is associated with a decreased risk of death in critically ill COVID-19 patients without obvious toxicity and its mechanisms of action is probably mediated through its inhibition of inflammatory cytokine storm on top of its ability in inhibiting viral replication. Therefore, hydroxychloroquine should be considered as a primary option to apply to treat critically ill COVID-19 patients, which could save lives during the current COVID-19 pandemic despite that randomized-double blind control study is needed to provide All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted May 1, 2020. . https://doi.org/10.1101/2020.04.27.20073379 doi: medRxiv preprint stronger evidence. Although this retrospective study was performed with the critically ill COVID-19 patients, hydroxychloroquine should also be an option for early stage of patients because the safety records and their long history of use in treating malaria infections. All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted May 1, 2020. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted May 1, 2020. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted May 1, 2020. . The percentage represented the frequency divided by the total cohort size (n=568). Mechanical ventilation contained Non-invasive ventilation and Invasive ventilation Data were presented as medians and interquartile range (Q1-Q3). HCQ, Hydroxychloroquine treatment; NHCQ, non-Hydroxychloroquine treatment. All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted May 1, 2020. Data were presented as medians and interquartile range (Q1-Q3). HCQ, hydroxychloroquine treatment; NHCQ, non-hydroxychloroquine treatment. All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted May 1, 2020. . https://doi.org/10.1101/2020.04.27.20073379 doi: medRxiv preprint Clinical Characteristics of Coronavirus Disease 2019 in China Chinese management guideline for COVID-19 (version 5.0) Compassionate Use of Remdesivir for Patients with Severe Covid-19 The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Aveolar Macrophage Activation and Cytokine Storm in the Pathogenesis of Severe COVID-19 Tocilizumab treatment in COVID-19: a single center experience An in vitro test system for compounds that modulate human inflammatory macrophage polarization COVID-19, cytokines and immunosuppression We thank all our colleagues from the Department of Internal Medicine, Tongji Hospital, as well as all the medical staffs fighting against COVID-19, for their tremendous efforts. We also thank Professor H. Eric Xu in Shanghai Institute of Materia Medica, Chinese Academy of Sciences for his great help in writing this paper.